SCHEMBL737677

SCHEMBL737677

CC(C)CCn1c(=O)[nH]c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.63
CYP1A2 P05177 2/20 0.63
KMT2A Q03164 2/20 0.63
LMNA P02545 4/20 0.59
HPGD P15428 2/20 0.59
HTT P42858 2/20 0.59
ALDH1A1 P00352 2/20 0.59
MAPT P10636 1/20 0.59
TSHR P16473 1/20 0.59
MAPK1 P28482 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
POLB P06746 2/20 0.55
RAB9A P51151 1/20 0.55
P2RX7 Q99572 5/20 0.51
HTR7 P34969 3/20 0.51
MLNR O43193 1/20 0.49
NR1I2 O75469 1/20 0.49
CHRM2 P08172 1/20 0.49
CYP3A4 P08684 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10284697 0.91 LMNA (0.64) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL2267066 0.83 CYP1A2 (0.67) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL763168 0.81 CYP1A2 (0.74) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL29695523 0.81 CYP1A2 (0.74) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL30947438 0.81 LMNA (0.78) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL10728078 0.80 MEN1 (0.58) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL738662 0.79 DAO (0.51) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL6902600 0.79 RAB9A (0.72) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL5243422 0.79 ERCC1 (0.46) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL6494898 0.78 LMNA (0.64) MEN1CYP1A2KMT2ALMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138177-B2 Benzimidazolone derivatives as CB2 receptor ligands PFIZER INC. (US) 2012-03-20 US disclosed
EP-1861377-B1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS PFIZER (US) 2010-12-29 EP disclosed
US-20090298811-A1 BENZIMIDAZOLONE DERIVATIVES PFIZER INC 2009-12-03 US disclosed
EP-2114897-A2 BENZIMIDAZOLONE DERIVATIVES Pfizer Products Inc. (US) 2009-11-11 EP disclosed
US-20090181957-A1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS ANDO KAZUO 2009-07-16 US disclosed
WO-2008032164-A2 BENZIMIDAZOLONE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-03-20 WO disclosed
EP-1861377-A1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS Pfizer, Inc. (US) 2007-12-05 EP disclosed
WO-2006097808-A1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS PFIZER JAPAN INC. (JP) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298811-A1 BENZIMIDAZOLONE DERIVATIVES TRPV1, CNR1, CNR2 MEN1 2819/4885CYP1A2 1782/4885KMT2A 4384/4885
US-20090181957-A1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS TRPV1, CNR1, CNR2 MEN1 3613/4885CYP1A2 1751/4885KMT2A 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.